

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

School of Biomedical Science

Master of Science Clinical Research

Mid Term Examination - May 2024

Duration : 90 Minutes

Max Marks : 50

Sem II - Q1PN202T - Clinical Trial DesigningGeneral Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- 1) Explain the (CFR) Code of federal regulation. K2 (2)
- 2) Define the Clinical Study protocol. K1 (3)
- 3) Explain the serious adverse event (SAE) and adverse event. K2 (4)
- 4) Explain the types of trials. K2 (6)
- 5) Illustrate the designing of phase I clinical research. K3 (6)
- 6) Illustrate Phase 2 clinical trial designing. K3 (9)
- 7) Analyze of declaration of helsinki (DoH). K4 (8)

- 8) Analyze the importance of safety and efficacy endpoints. K4 (12)

OR

Analyze the selection criteria and responsibility of principle investigator. K4 (12)